Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Sarah Scagliarini"'
Autor:
Cristian Lolli, Antonio Verde, Luca Degli Esposti, Valentina Acciai, Alessia Brigido, Emanuela Proietti, Sarah Scagliarini
Publikováno v:
Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)
Background: Cabozantinib use in everyday clinical practice for advanced or metastatic renal cell carcinoma (RCC) is relatively recent, and real-world data on treatment persistence, adherence and sequencing are still limited. Methods: We conducted an
Externí odkaz:
https://doaj.org/article/865fa36da71b4714ab07b497d096df32
Autor:
Gaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, Carla Cavaliere, Sarah Scagliarini, Maria Giuseppa Vitale, Chiara Ciccarese, Giuseppe Di Lorenzo, Erica Palesandro, Vincenza Conteduca, Umberto Basso, Emanuele Naglieri, Azzurra Farnesi, Michele Aieta, Nicolò Borsellino, Leonardo La Torre, Gelsomina Iovane, Lucia Bonomi, Donatello Gasparro, Enrico Ricevuto, Michele De Tursi, Rocco De Vivo, Giovanni Lo Re, Francesco Grillone, Paolo Marchetti, Ferdinando De Vita, Claudio Scavelli, Claudio Sini, Salvatore Pisconti, Anna Crispo, Vittorio Gebbia, Antonio Maestri, Luca Galli, Ugo De Giorgi, Roberto Iacovelli, Carlo Buonerba, Giacomo Cartenì, Carmine D’Aniello
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-11 (2019)
Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluate
Externí odkaz:
https://doaj.org/article/ce45764abe174be68515afe7c66b3135
Autor:
Maria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, Sandro Pignata, Giovanni Lo Re, Alfredo Berruti, Carlotta Defferrari, Massimiliano Spada, Cristina Masini, Daniele Santini, Libero Ciuffreda, Enzo Maria Ruggeri, Carmelo Bengala, Lorenzo Livi, Daniele Fagnani, Andrea Bonetti, Lucio Giustini, Alketa Hamzaj, Giuseppe Procopio, Claudia Caserta, Roberto Sabbatini
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0199642 (2018)
BACKGROUND:Results from phase III clinical trial CheckMate 025 have established nivolumab as the standard of care for treatment of metastatic renal-cell carcinoma (mRCC) after VEGF inhibitor failure; however, elderly patients are under-represented in
Externí odkaz:
https://doaj.org/article/d4bd7db75d9e42c5aea3c56d4c5c054a
Autor:
Sabrina Rossetti, Carmine D'Aniello, Gelsomina Iovane, Sarah Scagliarini, Maria M. Laterza, Fernando De Vita, Clementina Savastano, Giacomo Cartenì, Maria A. Porricelli, Massimiliano Berretta, Salvatore Pisconti, Gaetano Facchini, Carla Cavaliere
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outco
Externí odkaz:
https://doaj.org/article/fb8985c0ae524daba332bfa5ccac32e4
Autor:
Carlo Buonerba, Giuseppe Di Lorenzo, Gregory Pond, Giacomo Cartenì, Sarah Scagliarini, Antonio Rozzi, Fernando J Quevedo, Tanya Dorff, Lucia Nappi, Gaetano Lanzetta, Lance Pagliaro, Bernhard J. Eigl, Gurudatta Naik, Matteo Ferro, Sabino De Placido, Guru Sonpavde
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
AbstractIntroduction & objectives: Metastatic penile squamous cell carcinoma (PSCC) is associated with dismal outcomes with median overall survival (OS) of 6-12 months in the first-line and
Externí odkaz:
https://doaj.org/article/6eb7f95a51ca4ac0ab07710596c6f501
Autor:
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nolè, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni
Publikováno v:
Tumori Journal. 109:129-137
Background: First-line therapies based on immune-checkpoint inhibitors (ICIs) significantly improved survival of metastatic renal cell carcinoma (mRCC) patients. Cabozantinib was shown to target kinases involved in immune-escape and to prolong surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38ed0f887bc9e2033d6580f60025139
https://doi.org/10.1177/03008916221138881
https://doi.org/10.1177/03008916221138881
Autor:
Matteo Santoni, Zin W. Myint, Thomas Büttner, Hideki Takeshita, Yohei Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Küronya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, Robert Kemp, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina-Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popovic, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindrich Kopecky, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino M. Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta
Publikováno v:
Cancer Immunology, Immunotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d073e80624dad7dc9971e9ffe0fbfa8d
https://doi.org/10.1007/s00262-023-03469-5
https://doi.org/10.1007/s00262-023-03469-5
Autor:
Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Alessia Salfi, Thomas Büttner, Ugo De Giorgi, Ravindran Kanesvaran, Ondřej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R Matrana, Renate Pichler, Carlo Cattrini, Tomas Büchler, Emmanuel Seront, Fabio Calabrò, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Roubini Zakopoulou, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Ilaria Zampiva, Carlo Messina, Zsófia Küronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Ilaria Catalini, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Mimma Rizzo, Camillo Porta
Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f357fc06502ee653e2380faa5136fd
https://hdl.handle.net/10447/587700
https://hdl.handle.net/10447/587700
Autor:
Ciro Mauro, Valentina Capone, Rosangela Cocchia, Filippo Cademartiri, Ferdinando Riccardi, Michele Arcopinto, Maie Alshahid, Kashif Anwar, Mariano Carafa, Andreina Carbone, Rossana Castaldo, Salvatore Chianese, Giulia Crisci, Roberta D’Assante, Mariarosaria De Luca, Monica Franzese, Domenico Galzerano, Vincenzo Maffei, Alberto M. Marra, Valeria Valente, Federica Giardino, Alfredo Mazza, Brigida Ranieri, Anna D’Agostino, Salvatore Rega, Luigia Romano, Sarah Scagliarini, Chiara Sepe, Olga Vriz, Raffaele Izzo, Antonio Cittadini, Eduardo Bossone, Andrea Salzano
Cardiovascular (CV) diseases (CVD) are a major cause of long-term morbidity and mortality affecting life expectancy amongst cancer survivors. In recent years, because of the possibility of early diagnosis and the increased efficacy of neo-adjuvant an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fced885b159623a11ff38ddbef25a12d
https://hdl.handle.net/11588/917178
https://hdl.handle.net/11588/917178
Autor:
Ferdinando Riccardi, Bruno Chiurazzi, Raffaella Ruocco, Francesca Ambrosio, Maria Fiorella Brangi, Carmela Barbato, Vincenzo Di Lauro, Dario Arundine, M. Biglietto, Roberto Fiorentino, Francesco Jacopo Romano, Maresa Cammarota, Sarah Scagliarini, Livio Puglia, Ivana Cerillo, Carmen Mocerino
Publikováno v:
Oncotarget
The stock of therapeutic weapons available in metastatic colorectal cancer (mCRC) has been progressively grown over the years, with improving both survival and patients' clinical outcome: notwithstanding advances in the knowledge of mCRC biology, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b5a171e52b2a89d9e884a1160d08dc
https://doi.org/10.18632/oncotarget.27872
https://doi.org/10.18632/oncotarget.27872